LEGAL & REGULATORY
Scientific, Regulatory and Commercial Context Matters.
This page defines how public information on Pharmact, D016, BELACT®, evidence, partnering and separate application pathways should be interpreted. It does not replace product-specific, jurisdiction-specific, legal, regulatory, clinical or professional assessment.
Context defines interpretation. Access does not change regulatory status or create rights.
WEBSITE INFORMATION SCOPE
Scientific, technical, development, corporate and partnering information on this website must be read within the specific evidence level, intended use, development status, jurisdiction and contractual context to which it relates.
Technical characterization, preclinical results, external scientific context and historical observations are presented according to their source and evidentiary status.
Evidence from one level is not automatically evidence at another level.Development plans, regulatory interactions and future milestones describe a development pathway. They do not establish approval, clinical benefit, safety, designation or successful completion of future stages.
Development intent is not regulatory authorization.D016 may be discussed across distinct technical, supply, cosmetic and pharmaceutical contexts. Each context may require different specifications, documentation, claims support and regulatory assessment.
One technology does not create one regulatory status.Supply, technical discussion, disclosure, evaluation, licensing, co-development and ownership are distinct legal and commercial concepts governed by their applicable agreements.
Supply ≠ License ≠ Ownership.D016 · INTENDED-USE BOUNDARIES
The D016 technology platform may be developed or supplied in different contexts. Evidence, quality requirements, documentation, claims and regulatory responsibilities applicable to one pathway do not automatically transfer to another.
Public technical descriptions characterize D016 at a platform level. They do not, by themselves, define the specification or regulatory status required for every possible application.
Material supply is governed by the agreed grade, specification, documentation, intended-use conditions and commercial terms. Supply does not itself authorize a downstream product or use.
Cosmetic or topical development requires its own safety, formulation, claims, quality and market assessment for the finished product and the relevant jurisdiction.
BELACT is a distinct investigational pharmaceutical development program built around D016. Pharmaceutical development requirements are not established by non-pharmaceutical supply or cosmetic use.
BELACT® · INVESTIGATIONAL STATUS
BELACT remains an investigational pharmaceutical development program. No clinical safety or efficacy has been established for BELACT.
Preclinical findings, historical observations and regulatory-development interactions may inform development strategy, but they do not constitute marketing authorization or orphan designation and do not establish clinical benefit.
VIEW BELACT DEVELOPMENTPreclinical studies may support biological or development hypotheses. They do not establish human clinical efficacy or safety.
Uncontrolled observations with other enzyme sources are contextual evidence only and are not controlled D016 clinical evidence.
Regulatory-development interactions inform planning and expectations. They are not approvals or endorsements of safety, efficacy or future authorization.
Clinical safety and efficacy for BELACT have not been established.
Not established.EVIDENCE & REGULATORY DISTINCTIONS
These boundaries apply across scientific, development and public communication.
Animal, ex vivo, in vitro or other preclinical findings can inform development but cannot be presented as established patient benefit.
Observations involving different enzyme sources, uncontrolled treatment contexts or historical practice do not establish a controlled clinical result for D016 or BELACT.
Scientific advice and regulatory interactions support development planning. They do not constitute approval, authorization, designation or confirmation of safety or efficacy.
TOPICAL / COSMETIC BOUNDARY
Where D016 is evaluated in a topical or cosmetic context, the finished product remains subject to its own intended-use, formulation, safety, claims, quality, responsible-party and market requirements.
Technical documentation supplied for D016 can support evaluation of the ingredient. It does not by itself establish the safety, performance, regulatory acceptability or lawful claims of a third-party finished product.
Must be defined for the finished product and relevant market.
Require product-specific assessment and supporting documentation.
Must be supported at finished-product level and remain within the applicable cosmetic framework.
Remains with the legally responsible manufacturer, responsible person or other applicable market actor.
SUPPLY · LICENSING · INTELLECTUAL PROPERTY
Technical access and commercial discussions are structured according to the applicable agreement, rights, jurisdiction, field of use and transaction scope.
Receiving material, documentation or technical information does not itself grant a license, exclusivity, sublicensing right, commercialization right or ownership.
A license grants only the rights expressly defined in the applicable executed agreement, including any field, territory, application, term or commercialization scope.
Patent scope is determined by applicable claims. Freedom to operate is context-specific. Neither concept should be inferred from public website access or a material-supply relationship.
MEDICAL & PROFESSIONAL-USE LIMITATION
No content on this website should be interpreted as diagnosis, treatment advice, a recommendation to administer D016 or BELACT to a patient, or a substitute for professional medical judgment. BELACT remains investigational.
Patient-specific treatment requests and patient-identifiable health information should not be submitted through the public contact form. For medical decisions, consult an appropriately qualified healthcare professional. In an emergency, use the applicable local emergency service.
Scientific and development information is provided for professional, corporate and informational context.
CORPORATE, INVESTOR & FORWARD-LOOKING INFORMATION
Descriptions of development plans, milestones, timing, regulatory strategy, commercialization, partnerships, market opportunities or future transactions may depend on evidence, financing, technical execution, regulatory decisions, partner decisions and other factors outside Pharmact’s control.
Future plans and milestones describe current intent or planning assumptions and may be revised as evidence, risks, resources or regulatory context change.
Unless expressly stated in a legally applicable offering document, information on this website does not constitute an offer, solicitation or recommendation to acquire or dispose of securities or investment interests.
Confidential investor, licensing, diligence or transaction materials are governed by their own terms, disclosures, assumptions and applicable agreements.
U.S. CORPORATE RELATIONSHIP
Pantarhin Pharma LLC is an independent U.S. company working with Pharmact Holding AG in defined areas of pharmaceutical development, intellectual property, regulatory strategy and partnering.
References to D016 or BELACT® do not by themselves establish ownership of the underlying technology, unrestricted development rights, licensing authority or commercialization rights. The applicable corporate, intellectual-property and contractual documentation governs.
PANTARHIN LEGAL & REGULATORY →Pantarhin Pharma LLC operates pantarhin.com as a separate legal entity. References to or links between the websites do not, by themselves, create or transfer regulatory responsibility, contractual obligations or liability between the entities, except as expressly agreed or required by applicable law.
References to U.S.-related development do not imply FDA approval, U.S. commercial availability or authorization to promote an investigational pharmaceutical product.
JURISDICTION, CURRENCY & GOVERNING DOCUMENTS
Regulatory requirements, legal rights and product responsibilities can vary by jurisdiction, intended use, development stage and transaction structure. Website content may therefore be updated as evidence, legal status or development context changes. Website Summaries Do Not Replace the Applicable Governing Sources.
Executed agreements define or evidence patent status, ownership and applicable claim scope.
Current patent & legal records define or evidence patent status, ownership and applicable claim scope.
Applicable law and current regulatory records ggovern or document regulatory requirements, decisions and formal interactions.
Controlled product and quality documentation defines the applicable supplied material or product specification, subject to applicable legal and contractual requirements.
DEFINED CONTEXT
For a project-specific question, define the intended use, development stage, jurisdiction and required access so the appropriate technical, regulatory or commercial context can be applied.